128 related articles for article (PubMed ID: 1897286)
21. [Chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis].
Kawakami K
Kekkaku; 2002 Aug; 77(8):569-71. PubMed ID: 12235849
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
Bellabas M; Khaled S; Khaled NA; Boulahbal F; Chaulet P
Rev Mal Respir; 1989; 6(1):59-64. PubMed ID: 2648511
[TBL] [Abstract][Full Text] [Related]
23. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
[TBL] [Abstract][Full Text] [Related]
24. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
McIlleron H; Norman J; Kanyok TP; Fourie PB; Horton J; Smith PJ
J Antimicrob Chemother; 2007 Dec; 60(6):1398-401. PubMed ID: 17951604
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
26. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
27. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
Zierski M; Bek E
Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
[No Abstract] [Full Text] [Related]
28. [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
Morland L
Tidsskr Nor Laegeforen; 1990 Nov; 110(28):3608-11. PubMed ID: 2260057
[TBL] [Abstract][Full Text] [Related]
29. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
[TBL] [Abstract][Full Text] [Related]
30. Serum concentration of isoniazid following administration of the drug alone and in combination with rifampicin in patients of pulmonary tuberculosis.
Singhal KC; Rathi R; Kishore K; Varshney SC; Varshney DP
Indian J Physiol Pharmacol; 1986; 30(1):115-7. PubMed ID: 3818028
[No Abstract] [Full Text] [Related]
31. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
32. Modern treatment of tuberculosis.
Dutt AK; Stead WW
Compr Ther; 1982 Sep; 8(9):19-28. PubMed ID: 7140206
[No Abstract] [Full Text] [Related]
33. Tuberculosis treatment: dangerous regimens?
Rieder HL; Arnadottir T; Trébucq A; Enarson DA
Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
[No Abstract] [Full Text] [Related]
34. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
Jain A; Mehta VL; Kulshrestha S
Tuber Lung Dis; 1993 Apr; 74(2):87-90. PubMed ID: 8324212
[TBL] [Abstract][Full Text] [Related]
35. [Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
Nikodemowicz E; Kamińska M; Kopeć H; Maternowska W; Prus F; Sembratowicz L
Pneumonol Pol; 1986 Jan; 54(1):9-15. PubMed ID: 3714521
[No Abstract] [Full Text] [Related]
36. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Lambert LA; Ijaz K; Navin TR
Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
[No Abstract] [Full Text] [Related]
37. [New and future drugs in pulmonary tuberculosis].
Grosset JH; Truffot-Pernot C; Lecoeur H
Prax Klin Pneumol; 1988 Jun; 42 Suppl 1():206-10. PubMed ID: 3174565
[No Abstract] [Full Text] [Related]
38. [Therapy of tuberculosis in the adult].
Schrappe M; Wassermann K; Kroegel C
Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
[No Abstract] [Full Text] [Related]
39. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Brändli O; Dreher D; Morger D
Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
[TBL] [Abstract][Full Text] [Related]
40. [Intravenous rifampicin therapy in open tuberculosis].
Loos U; Musch E; Mackes KG; Reetz KP; Gläser R; Schwabe HK; Hengstmann J; Eichelbaum M
Med Welt; 1983 Jun; 34(24):701-3. PubMed ID: 6888237
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
